Christopher LiPuma

Managing Director



Mr. LiPuma is a Managing Director in San Francisco in Fortress’s Intellectual Property Group, where he focuses on a wide variety of investment opportunities in connection with intellectual property, life sciences, and academic institutions.

Prior to joining Fortress in 2018, Mr. LiPuma headed business development for Kastle Therapeutics, a private equity-backed biotechnology company acquiring ultra-orphan drugs. Before joining Kastle, he was with OrbiMed Advisors, a life sciences-focused asset management firm. At OrbiMed, he worked on royalty monetizations, direct lending to late development stage and early commercial stage life sciences companies, and several private equity transactions focused on acquiring legacy assets from big pharma. He started his career as an investment banker at Leerink Partners.

Mr. LiPuma holds a B.A. from Hamilton College.

9:55 AM - 10:25 AM

Wednesday March 6, 2024

Why is Venture Debt a Terrible Idea?

  • The good, bad, and ugly of venture debt
  • When is venture debt a poor plan?
  • Using venture debt wisely to fund growth